Eli Lilly Q3 earnings expected to beat Wall Street expectations
In This Article:
Eli Lilly (LLY) is expected to easily beat Wall Street's expectations when it reports third quarter earnings Wednesday morning before the bell, especially for its blockbuster weight-loss drug Zepbound. The GLP-1 drug continues to be a focal point of the company's near-term outlook.
Eli Lilly is expected to report $12.17 billion in revenue for the quarter and adjusted earnings per share of $1.51, according to Bloomberg consensus estimates.
Mizuho's healthcare expert Jared Holz wrote in a note to clients today that sales for Zepbound are estimated at $1.7 billion, while diabetes drug Mounjaro could slightly miss estimates of $3.8 billion as more patients turn to Zepbound for its higher-dosage weight-loss benefit.
And that tracks what investors are watching, Holz said.
"Some have asserted that the stock and group have peaked," he wrote. "Given the complexities around much of the Healthcare sector and difficulty establishing a simple thesis for the vast majority of names in Pharma/Biotech or otherwise, we think investors will remain very engaged in weight-loss names."
Lilly posted $4.3 billion in revenue last quarter from the two drugs.
Eli Lilly and Company (LLY)
最新報道
- 02-19DeepSeek發布NSA 訓練推理加
- 01-28有生之年系列，iPhone 版 What
- 12-09馬雲現身賀螞蟻20歲 稱未來A
- 11-28華為 Mate 70 發佈用「純血
- 11-28傳 Nintendo Switch 2 將預
- 11-28中國版 RTX 5090D 硬件或與
- 11-28黃仁勳科大送10張RTX 4060 T
- 11-07首款彩色屏幕 Kindle 閱讀器
- 11-07WhatsApp 加入聊天清單功能
- 11-07俄羅斯推動加密貨幣 挖礦合